REG - Abingdon Health PLC - Notice of Results

Abingdon HealthAnnouncement

04/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241004:nRSD9104Ga&default-theme=true

RNS Number : 9104G  Abingdon Health PLC  04 October 2024

 

Abingdon Health plc

("Abingdon" or "the Company")

 

Notice of Results

Investor Presentation

 

York, U.K.  4 October 2024: Abingdon Health plc (AIM: ABDX), a leading
international lateral flow contract research (CRO) and contract development
and manufacturing organisation (CDMO), announces that it expects to release
its preliminary results for the year ended 30 June 2024 on Tuesday 8 October.

 

Investor Presentation

The Company will provide a live presentation relating to the preliminary
results via the Investor Meet Company platform on Tuesday 8 October at 9.30am
BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Abingdon Health plc via:

 

https://www.investormeetcompany.com/abingdon-health-plc/register-investor
(https://www.investormeetcompany.com/abingdon-health-plc/register-investor)

 

Investors who already follow Abingdon Health plc on the Investor Meet Company
platform will automatically be invited.

 

Enquiries:

 

 Abingdon Health plc                                                       www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                      Via Walbrook PR
 Chris Hand, Non-Executive Chairman

 Zeus Capital (Sole Broker and Nominated Adviser)                            Tel: +44 (0)20 3829 5000
 Chris Fielding / Isaac Hooper (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
 Phillip Marriage                              +44 (0)7867 984 082

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Company's CDMO division
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.abingdonhealth.com_services_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=HA76POaNPDBWSuSNqpvm6h6sTVAmwDfGPxyLLvvNBHg&e=)
offers lateral flow product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health's CDMO division has the internal capabilities to take
lateral flow projects, in areas such as infectious disease and clinical
testing, including companion diagnostics, animal health and environmental
testing, from initial concept through to routine and large-scale
manufacturing; from "idea to commercial success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
(https://urldefense.proofpoint.com/v2/url?u=https-3A__cslifesciences.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=PvbE1xuJgNrAaK0I9QSrYjO3acai4ITHsbheoH-Cavc&e=)
and IVDeology
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ivdeology.co.uk&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=mbRruUP_NEre93fFYpNkBweGVcmSCnXpjUyMQmUx1yI&e=)
, provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonsimplytest.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=71SLyhJsm1hJqJvXuK0jPc4-fr_IZIW_VOOfo4sJwQw&e=)
e-commerce site offers consumers a range of information to support them in
making informed decisions on the tests available. In addition, the site
provides Abingdon's contract services customers with a potential route to
market for self-tests. The Abingdon Simply Test range is also sold through
international distributors and through other channels in the UK and Ireland,
such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDBBDGRDGDGSX